<DOC>
	<DOC>NCT01316835</DOC>
	<brief_summary>This study will evaluate whether the addition of sitagliptin treatment provides additional decrease in HbA1C levels and increase in goal attainment in patients with inadequate glycemic control on their current oral anti-glycemic therapy in real world practice.</brief_summary>
	<brief_title>Effectiveness of Sitagliptin in Glycemic Control in Real World</brief_title>
	<detailed_description>To explore the change of glycemic control (HbA1c or FPG) before and after 24 weeks of Sitagliptin treatment in Type 2 Diabetic patients who have started Sitagliptin as add on therapy during the index period and received Sitagliptin continuously* for at least 24 weeks.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1. All subjects diagnosed of type 2 diabetes (ICD9 code= 250.0; 250.1; 250.2; 250.3; 250.4; 250.5; 250.6) and have been followed up regularly in the study center who have started to receive Sitagliptin as an addon treatment to their prior regimen during the index period 2. Subjects must be on a stable dose of all antidiabetic regimens, with stable dose defined as "at least 3 months with no therapy/dose change" prior to adding sitagliptin 3. Subjects in whose medical records a minimum core data set can be found. 4. Outpatient 1. Subjects with type 1 DM 2. Subjects have been treated with insulin regularly 3. Subject with DM which results from other general diseases, e.g. surgery, pharmaceutical products, malnutrition, infections and other conditions 4. Subjects who participated in a clinical trial or other clinical study during the index period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>retrospective,sitagliptin, glycemia control,real world</keyword>
</DOC>